Compare PMI & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMI | BNGO |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | United States |
| Employees | 75 | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 12.9M |
| IPO Year | N/A | 2018 |
| Metric | PMI | BNGO |
|---|---|---|
| Price | $0.15 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 6.3M | 132.0K |
| Earning Date | 06-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.11 | $1.06 |
| 52 Week High | $13.68 | $5.50 |
| Indicator | PMI | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 42.99 |
| Support Level | $0.15 | $1.13 |
| Resistance Level | $0.27 | $1.19 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 18.51 | 21.43 |
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.